Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899049 | 0.95 | KIF11 (0.52) | KIF11ALDH1A1TSHRATMMEN1 | |
| SCHEMBL5899077 | 0.94 | KIF11 (0.54) | KIF11ALDH1A1TSHRATMPOLB | |
| SCHEMBL5899064 | 0.92 | KIF11 (0.57) | KIF11 | |
| SCHEMBL5899063 | 0.90 | KIF11 (0.51) | KIF11ALDH1A1POLB | |
| SCHEMBL4042910 | 0.89 | KIF11 (0.64) | KIF11 | |
| SCHEMBL5899015 | 0.88 | KIF11 (0.49) | KIF11ALDH1A1POLBLMNASMN1; SMN2 | |
| SCHEMBL4037105 | 0.88 | KIF11 (0.56) | KIF11 | |
| SCHEMBL5899039 | 0.88 | KIF11 (0.49) | KIF11ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL5787670 | 0.87 | ALDH1A1 (0.40) | KIF11ALDH1A1TSHRATMMEN1 | |
| SCHEMBL4036044 | 0.86 | KIF11 (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1628981-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106492-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | KIF11 257/4885ALDH1A1 1375/4885TSHR 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.